BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $1801.HK readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07122687-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pemetrexed readout (P2) · Innovent Biologics (Suzhou) Co. Ltd. $18
 01.HK
DESCRIPTION:IBI363 Combined With Chemotherapy or Pembrolizumab Combined Wit
 h Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squam
 ous Non-Small Cell Lung Cancer\n\nPrimary completion date: 2026-11-30 (est
 imated)\nPhase 2 · Oncology · Resectable Stage IB-III Non-Squamous Non-S
 mall Cell Lung Ca…\nEnrollment: 170 · Sites: 1\n\nPrimary completion = 
 last participant's primary-endpoint data collected\; topline results usual
 ly follow weeks to months later. Sponsor-reported\, often an estimate. Not
  investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07122687\n
 https://clinicaltrials.gov/study/NCT07122687
URL:https://datacutoff.com/radar.html?nct=NCT07122687
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238843-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:G-HOPE-001 readout (P3) · Innovent Biologics (Suzhou) Co. Ltd. $18
 01.HK
DESCRIPTION:A Multicenter\, Phase 3 Study of IBI343 Monotherapy Versus Trea
 tment of Investigator's Choice in Subjects With Previously Treated\, Claud
 in (CLDN) 18.2-positive\, HER2-negative\, Gast…\n\nPrimary completion da
 te: 2026-12-30 (estimated)\nOriginally planned: 2026-05-30 (+7.0 months)\n
 Phase 3 · Oncology · Unresectable or Metastatic Gastric or Gastroesophag
 eal Junc…\nEnrollment: 464 · Sites: 95\n\nPrimary completion = last par
 ticipant's primary-endpoint data collected\; topline results usually follo
 w weeks to months later. Sponsor-reported\, often an estimate. Not investm
 ent advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06238843\nhttps://
 clinicaltrials.gov/study/NCT06238843
URL:https://datacutoff.com/radar.html?nct=NCT06238843
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797297-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI363 readout (P2) · Innovent Biologics (Suzhou) Co. Ltd. $1801.H
 K
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of IBI363 Monothera
 py Compared to Pembrolizumab in Patients With Unresectable Locally Advance
 d or Metastatic Mucosal or Acral Melanoma …\n\nPrimary completion date: 
 2026-12-31 (estimated)\nOriginally planned: 2026-03-31 (+9.0 months)\nPhas
 e 2 · Oncology · Melanoma\nEnrollment: 203 · Sites: 31\n\nPrimary compl
 etion = last participant's primary-endpoint data collected\; topline resul
 ts usually follow weeks to months later. Sponsor-reported\, often an estim
 ate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06
 797297\nhttps://clinicaltrials.gov/study/NCT06797297
URL:https://datacutoff.com/radar.html?nct=NCT06797297
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06884293-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI362 readout (P3) · Innovent Biologics (Suzhou) Co. Ltd. $1801.H
 K
DESCRIPTION:A Study Comparing IBI362 vs Semaglutide in Chinese Overweight o
 r Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease 
 （MAFLD）\n\nPrimary completion date: 2026-12-31 (estimated)\nPhase 3 ·
  Cardio-Met · Overweight\, Metabolic Dysfunction-associated Fatty Liver D
 isease (MAFLD)\nEnrollment: 479 · Sites: 1\n\nPrimary completion = last p
 articipant's primary-endpoint data collected\; topline results usually fol
 low weeks to months later. Sponsor-reported\, often an estimate. Not inves
 tment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06884293\nhttps:
 //clinicaltrials.gov/study/NCT06884293
URL:https://datacutoff.com/radar.html?nct=NCT06884293
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908876-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI302 readout (P2) · Innovent Biologics Technology Limited (Shang
 hai R&D Center) $1801.HK
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of IBI302 inSubject
 s With Diabetic Macular Edema（DME）\n\nPrimary completion date: 2026-12
 -31 (estimated)\nPhase 2 · Cardio-Met · Diabetic Macular Oedema\nEnrollm
 ent: 150 · Sites: 1\n\nPrimary completion = last participant's primary-en
 dpoint data collected\; topline results usually follow weeks to months lat
 er. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:
 //datacutoff.com/radar.html?nct=NCT06908876\nhttps://clinicaltrials.gov/st
 udy/NCT06908876
URL:https://datacutoff.com/radar.html?nct=NCT06908876
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113262-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI311 readout (P3) · Innovent Biologics (Suzhou) Co. Ltd. $1801.H
 K
DESCRIPTION:A Clinical Study to Evaluate the Efficacy and Safety of IBI311 
 in Subjects With Inactive Thyroid Eye Disease\n\nPrimary completion date: 
 2026-12-31 (estimated)\nPhase 3 · Rare · Thyroid Eye Disease\nEnrollment
 : 111 · Sites: 1\n\nPrimary completion = last participant's primary-endpo
 int data collected\; topline results usually follow weeks to months later.
  Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://d
 atacutoff.com/radar.html?nct=NCT07113262\nhttps://clinicaltrials.gov/study
 /NCT07113262
URL:https://datacutoff.com/radar.html?nct=NCT07113262
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07402070-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI363 readout (P2) · Innovent Biologics (Suzhou) Co. Ltd. $1801.H
 K
DESCRIPTION:IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Sm
 all Cell Lung Cancer\n\nPrimary completion date: 2026-12-31 (estimated)\nP
 hase 2 · Oncology · Resectable Stage II-III Non-small Cell Lung Cancer\n
 Enrollment: 10 · Sites: 1\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://datacutoff.com/radar.html?nct=NCT07402070\nhttps://clinicaltrials.
 gov/study/NCT07402070
URL:https://datacutoff.com/radar.html?nct=NCT07402070
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764861-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dexamethasone readout (P2) · Innovent Biologics (Suzhou) Co. Ltd. 
 $1801.HK
DESCRIPTION:A Open-Label Phase in Participants With Multiple Myeloma\n\nPri
 mary completion date: 2026-12-31 (estimated)\nPhase 2 · Oncology · Multi
 ple Myeloma\nEnrollment: 120 · Sites: 1\n\nPrimary completion = last part
 icipant's primary-endpoint data collected\; topline results usually follow
  weeks to months later. Sponsor-reported\, often an estimate. Not investme
 nt advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07764861\nhttps://c
 linicaltrials.gov/study/NCT07764861
URL:https://datacutoff.com/radar.html?nct=NCT07764861
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05972473-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Aflibercept Ophthalmic readout (P3) · Innovent Biologics (Suzhou) 
 Co. Ltd. $1801.HK
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of IBI302 in Subjec
 ts With nAMD\n\nPrimary completion date: 2027-02-28 (estimated)\nPhase 3 
 · Eye · Neovascular Age-related Macular Degeneration\nEnrollment: 600 ·
  Sites: 1\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://datacutof
 f.com/radar.html?nct=NCT05972473\nhttps://clinicaltrials.gov/study/NCT0597
 2473
URL:https://datacutoff.com/radar.html?nct=NCT05972473
CATEGORIES:Eye,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07399067-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:IBI3002 readout (P2) · Innovent Biologics (Suzhou) Co. Ltd. $1801.
 HK
DESCRIPTION:A Proof-of-Concept Study of IBI3002 in Patients With Moderate t
 o Severe Atopic Dermatitis\n\nPrimary completion date: 2027-03-23 (estimat
 ed)\nPhase 2 · Immuno · Atopic Dermatitis\nEnrollment: 120 · Sites: 1\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT07399067\nhttps://clinicaltrials.gov/study/NCT07399067
URL:https://datacutoff.com/radar.html?nct=NCT07399067
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07414394-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Febuxostat readout (P3) · Innovent Biologics Technology Limited (S
 hanghai R&D Center) $1801.HK
DESCRIPTION:Tigulixostat (IBI128) vs Febuxostat in Gout\n\nPrimary completi
 on date: 2027-04-30 (estimated)\nPhase 3 · Rare · Gout\nEnrollment: 600 
 · Sites: 1\n\nPrimary completion = last participant's primary-endpoint da
 ta collected\; topline results usually follow weeks to months later. Spons
 or-reported\, often an estimate. Not investment advice.\n\nhttps://datacut
 off.com/radar.html?nct=NCT07414394\nhttps://clinicaltrials.gov/study/NCT07
 414394
URL:https://datacutoff.com/radar.html?nct=NCT07414394
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931028-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270507
DTEND;VALUE=DATE:20270508
SUMMARY:IBI362 readout (P3) · Innovent Biologics (Suzhou) Co. Ltd. $1801.H
 K
DESCRIPTION:A Study of IBI362 in Chinese Subjects With Obstructive Sleep Ap
 nea and BMI≥28 kg/m2\n\nPrimary completion date: 2027-05-07 (estimated)\
 nPhase 3 · Neuro · Sleep Apnea\, Obstructive\, Obesity\nEnrollment: 260 
 · Sites: 1\n\nPrimary completion = last participant's primary-endpoint da
 ta collected\; topline results usually follow weeks to months later. Spons
 or-reported\, often an estimate. Not investment advice.\n\nhttps://datacut
 off.com/radar.html?nct=NCT06931028\nhttps://clinicaltrials.gov/study/NCT06
 931028
URL:https://datacutoff.com/radar.html?nct=NCT06931028
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07842497-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270511
DTEND;VALUE=DATE:20270512
SUMMARY:Compound Betamenth Group readout (P2) · Innovent Biologics (Suzhou
 ) Co. Ltd. $1801.HK
DESCRIPTION:A Study of Efficacy and Safety of IBI3011 in Subjects With Acut
 e Gouty Arthritis\n\nPrimary completion date: 2027-05-11 (estimated)\nPhas
 e 2 · Immuno · Acute Gouty Arthritis\nEnrollment: 132 · Sites: 1\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html
 ?nct=NCT07842497\nhttps://clinicaltrials.gov/study/NCT07842497
URL:https://datacutoff.com/radar.html?nct=NCT07842497
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07066098-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:IBI343 readout (P3) · Innovent Biologics (Suzhou) Co. Ltd. $1801.H
 K
DESCRIPTION:A Multicenter Study of IBI343 Monotherapy Versus Placebo in Sub
 jects With Previously Treated\, Claudin (CLDN) 18.2-positive\, Pancreatic 
 Cancer(G-HOPE-002)\n\nPrimary completion date: 2027-06-30 (estimated)\nPha
 se 3 · Oncology · Pancreatic Cancer\nEnrollment: 201 · Sites: 1\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT07066098\nhttps://clinicaltrials.gov/study/NCT07066098
URL:https://datacutoff.com/radar.html?nct=NCT07066098
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255209-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:IBI362 readout (P3) · Innovent Biologics (Suzhou) Co. Ltd. $1801.H
 K
DESCRIPTION:A Study of IBI362 in Chinese Adolescents With Obesity or Overwe
 ight\n\nPrimary completion date: 2027-10-31 (estimated)\nPhase 3 · Cardio
 -Met · Adolescents With Obesity or Overweight With Weight-Related …\nEn
 rollment: 180 · Sites: 1\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://datacutoff.com/radar.html?nct=NCT07255209\nhttps://clinicaltrials.g
 ov/study/NCT07255209
URL:https://datacutoff.com/radar.html?nct=NCT07255209
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836660-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Part A - Placebo for IBI355 readout (P2) · Innovent Biologics (Suz
 hou) Co. Ltd. $1801.HK
DESCRIPTION:A Study of IBI355 in Participants With Moderate-to-Severe Sjög
 ren's Disease\n\nPrimary completion date: 2027-11-01 (estimated)\nPhase 2 
 · Immuno · Sjögren's Disease\nEnrollment: 198 · Sites: 1\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NC
 T07836660\nhttps://clinicaltrials.gov/study/NCT07836660
URL:https://datacutoff.com/radar.html?nct=NCT07836660
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
